FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023346881> ?p ?o ?g. }

• W2023346881 endingPage "675" @default.
• W2023346881 startingPage "666" @default.
• W2023346881 abstract "AllergyVolume 51, Issue 10 p. 666-675 Free Access The clinical safety of H1-receptor antagonists: An EAACI position paper* G. Passalacqua, G. PassalacquaSearch for more papers by this authorJ. Bousquet, J. BousquetSearch for more papers by this authorC. Bachert, C. BachertSearch for more papers by this authorM. K. Church, M. K. ChurchSearch for more papers by this authorC. Bindslev-Jensen, C. Bindslev-JensenSearch for more papers by this authorL. Nagy, L. NagySearch for more papers by this authorP. Szemere, P. SzemereSearch for more papers by this authorR. J. Davies, R. J. DaviesSearch for more papers by this authorS. R. Durham, S. R. DurhamSearch for more papers by this authorF. Horak, F. HorakSearch for more papers by this authorK. Kontou-Fili, K. Kontou-FiliSearch for more papers by this authorH.-J. Malling, H.-J. MallingSearch for more papers by this authorP. van Cauwenberge, P. van CauwenbergeSearch for more papers by this authorG. W. Canonica, Corresponding Author G. W. CanonicaCanonica Allergy and Clinical Immunology Service DIMI Department of Internal Medicine Genoa University Viale Benedetto XV, 6, 16132 Genova ItalySearch for more papers by this author G. Passalacqua, G. PassalacquaSearch for more papers by this authorJ. Bousquet, J. BousquetSearch for more papers by this authorC. Bachert, C. BachertSearch for more papers by this authorM. K. Church, M. K. ChurchSearch for more papers by this authorC. Bindslev-Jensen, C. Bindslev-JensenSearch for more papers by this authorL. Nagy, L. NagySearch for more papers by this authorP. Szemere, P. SzemereSearch for more papers by this authorR. J. Davies, R. J. DaviesSearch for more papers by this authorS. R. Durham, S. R. DurhamSearch for more papers by this authorF. Horak, F. HorakSearch for more papers by this authorK. Kontou-Fili, K. Kontou-FiliSearch for more papers by this authorH.-J. Malling, H.-J. MallingSearch for more papers by this authorP. van Cauwenberge, P. van CauwenbergeSearch for more papers by this authorG. W. Canonica, Corresponding Author G. W. CanonicaCanonica Allergy and Clinical Immunology Service DIMI Department of Internal Medicine Genoa University Viale Benedetto XV, 6, 16132 Genova ItalySearch for more papers by this author First published: October 1996 https://doi.org/10.1111/j.1398-9995.1996.tb02109.xCitations: 30 † *EAACI Subcommittee on Antiallergic Drugs: C. Bachert (Germany), J. Bousquet (France), C. Bindslev-Jensen (Denmark), G. W. Canonica (Italy), M. K. Church (UK), R. J. Davies (UK), S. R. Durham (UK), F. Horak (Austria), K. Kontou-Fili (Greece), H.-J. Malling (Denmark), L. Nagy (Hungary), G. Passalacqua (Italy), P. Szemere (Hungary), P. van Cauwenberge (Belgium). AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Simons FER. A new classification of H1-receptor antagonists. Allergy 1995; 50 Suppl 24: 7 – 11. 2 Dale HH, Laidlaw PP. The physiological action of beta-imidazolylethilamine. J Physiol 1910; 41: 318 – 44. 3 Lewis T. The blood vessels of the human skin and their response. London : Shaw & Sons. 1927. 4 Ash ASF, Schild HO. Receptors mediating some actions of histamine. Br J Pharmacol 1966; 27: 427 – 39. 5 Black W, Dunian WAM, Durant CJ, Ganellin CR, Parsons EM. Definition and antagonism of histamine H2 receptors. Nature 1972; 236: 385 – 90. 6 Arrang JM, Garbarg M, Lancelot JC, Lecomte JM, Schwartz JC. Highly potent and selective ligands for histamine H, receptors. Nature 1987; 327: 117 – 23. 7 Staub AM, Bovet D. Action de la thymoxyethil-diethyl-amine et des Ctheres phenoliques sur le choc anaphylactique du cobaye. CR Soc Biol 1937; 125: 818. 8 Goldberg MJ, Spector R, Chiang CK. Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther 1987; 240: 717 – 22. 9 Janssens MML, Howarth P. The antihistamines of the 'nineties. Clin Rev Allergy 1993; 11: 111 – 53. 10 Timmermann H. Factors involved in the incidence of central nervous system effects of H1 blockers. In: MK Church, JP Rhioux, editors. Therapeutic index of antihistamines. Lewiston , NY . Hogrefe & Huber, 1992: 19 – 31. 11 Ahn HS, Barnett A. Selective displacement of 3H mepyramine from peripheral vs central nervous system receptors by loratadine, a non-sedating antihistamine. Eur J Pharmacol 1986; 127: 153 – 5. 12 Ruat M, Bouthenet ML, Schwartz JC, Ganellin CR. Histamine H1 receptor in health: unique electrophoretic mobility and autoradiographic localization. J Neurochem 1990; 55: 379 – 85. 13 Simons FER, Simons KJ. Pharmacokinetic optimisation of histamine H1-receptor antagonists. Clin Pharmacokinet 1991; 21: 372 – 93. 14 Simons FER, Simons KJ. Second-generation H1-receptor antagonists. Ann Allergy 1991; 66: 5 – 19. 15 Simons KJ, Martin TJ, Watson WTA, Simons FER. Pharmacokinetics and pharmacodynamics of terfenadine and chlorpheniramine in the elderly. J Allergy Clin Immunol 1990; 85: 540 – 7. 16 Simons FER, McMillan JL, Simons KJ. A double-blind, single-dose, crossover comparison of cetirizine, terfenadine, loratadine, astemizole and chlorpheniramine versus placebo: suppressive effects on histamine-induced wheal and flares during 24 hours in normal subjects. J Allergy Clin Immunol 1990; 86: 540 – 7. 17 Benoit C, Malo JL, Ghezzo B, Cartier A. Single dose of astemizole effect on bronchoconstriction induced by histamine in asthmatic subjects. Chest 1992; 101: 1318 – 25. 18 Lantin JP, Huguenot CH, Pécoud A. Effect of the H1 antagonist astemizole on the skin reaction by histamine, codein and allergens. Curr Ther Res 1990; 47: 683 – 92. 19 Tyolahti H, Lahti A. Start and end of the effects of terfenadine and astemizole on histamine induced wheals in human skin. Acta Derm Venereol (Stockh) 1989; 69: 269 – 71. 20 Kassem N, Roman I, Gural R, Dyer JG, Robillard N. Effects of loratadine (SCH29851) in suppression of histamine induced skin wheals. Ann Allergy 1988; 60: 505 – 7. 21 Horak F, Jager S, Berger U. Onset and duration of the effects of three antihistamines in current use - astemizole, loratadine and terfenadine forte - studied during prolonged controlled allergen challenge in volunteers. J Int Med Res 1992; 20: 422 – 34. 22 Juhlin L, de Vos C, Rihoux JP. Inhibiting effect of cetirizine on histamine induced and 40/80 induced wheals and flares, experimental dermographism and cold induced urticaria. J Allergy Clin Immunol 1987; 80: 599 – 602. 23 Rihoux JP, Dupont P. Comparative study of the peripheral and central effects of terfenadine and cetirizine 2HCl. Ann Allergy 1987; 59: 235 – 8. 24 Gould CAL, Ollier S, Aurich R, Davies RJ. A study of the clinical efficacy of azelastine in patients with extrinsic asthma and its effect on airways responsiveness. Br J Clin Pharmacol 1988; 5: 515 – 25. 25 Dechant KL, Goa KL. Levocabastine: a review of its pharmacological properties and therapeutic potential as a topic antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 202 – 24. 26 Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987; 59: 31 – 4. 27 Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617 – 37. 28 McQuade RD, Richlan K, Duffy RA, Chipkin RE, Barnett A. In vivo properties of non-sedating antihistamines to CNS histamine receptors. Drug Develop Res 1990; 20: 301 – 6. 29 Nicholson AN, Pascoe PA, Ston BM. Histaminergic systems and sleep. Studies in man with H1 and H2 antagonists. Neuropharmacology 1985; 24: 245 – 50. 30 Cimbura G, Lucas DM, Bennet RC, Warren RA, Simpson HM. Incidence and toxicological aspects of drugs detected in 484 fatally injured drivers and pedestrians in Ontario. J Forensic Sci 1982; 27: 855 – 67. 31 Passalacqua G, Scordamaglia A, Ruffoni S, Parodi MN, Canonica GW. Sedation from H1 antagonists: evaluation methods and experimental results. Allergol Immunopathol (Madr) 1993; 21: 79 – 83. 32 Simons FER. H1 receptor antagonists: comparative tolerability and safety. Drug Safety 1994; 10: 350 – 80. 33 O'Hanlon JF. Driving performance under the influence of drugs; rationale for, and application of, a new test. Br J Clin Pharmacol 1984; 18: 121S – 9S. 34 Dhorranintra B, Limsuvan S, Bunnag C. Effect of astemizole on psychomotor performance in healthy subjects. Drug Res 1986; 7: 285 – 90. 35 Hindmarch I, Bhatti JA. Psychomotor effects of astemizole and chlorpheniramine. alone and in combination with alcohol. Int Clin Psychopharmacol 1987; 2: 117 – 19. 36 Bateman DN, Chapman PH, Rawlins MD. Lack of effects of astemizole on ethanol dynamics or kinetics. Eur J Clin Pharmacol 1983; 25: 567 – 8. 37 Moser VL, Gerdes H, Buckmann M, Hopmann G. Anti-histaminika und Reaktion Fähigkeit. Arzneimittel-forschung 1983; 33: 262 – 5. 38 Kohl RL, Homick JL, Cintron N, Kalkins DS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness and cognitive performance in man. Aviat Space Environ Med 1987; 58: 1171 – 4. 39 Betts TA, Edson AE, Furlong PI. The effects of single doses of 120 and 240 mg of terfenadine on driving and other measures of psychomotor performance including visual evoked responses. Ann Allergy 1991; 66: 98. 40 Bhatti JA, Hindmarch I. The effects of terfenadine with and without alcohol on an aspect of car driving performance. Clin Exp Allergy 1989; 19: 609 – 11. 41 Kulshrestha VK, Gupta PP, Turner P, Wadsworth J. Some clinical pharmacological studies with terfenadine, a new antihistamine. Br J Clin Pharmacol 1978; 6: 25 – 9. 42 Moskovitz H, Burns M. Effects of terfenadine, diphenhydramine or placebo on skill performances. Cutis 1988; 42: 14 – 18. 43 Goetz DW, Jacobson JM, Apaliski SJ, Repperger DW, Martin ME. Objective antihistamine side effects are mitigated by an evening dosing of hydroxyzine. Ann Allergy 1991; 67: 448 – 54. 44 Loring DW, Meador KJ. Central nervous system effects of antihistamines on evoked potentials. Ann Allergy 1989; 63: 604 – 8. 45 Murri L, Massetani R, Krause M, Dragonetti C, Iudicc A. Evaluation of antihistamine related daytime sleepiness. Allergy 1992; 47: 532 – 4. 46 Bonifazi F, Provinciali I, Antonicelli L, et al. Comparative study of kerfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J Invest Allergol Clin Immunol 1995; 5: 40 – 6. 47 Riedel WJ, Schoenmakers EA, O'Hanlon JF. Sedation and performance impairment with antihistamines. In: MA Kalinger, editor. Management of allergy in the 1990s. Toronto : Huher, 1990: 38 – 44. 48 Betts T, Wild J, Ross K, Kenwood C, Thirtle-Watts R. A double-blind, single-dose study of the effects of loratatline on driving skills in normal volunteers. In: MA Kalinger, editor. Management of allergy in the 1990s. Toronto : Huber, 1990: 74 – 8. 49 Adelsberg BR, D'Amico-Beadon A. The effects of loratadine, diphenhydramine or placebo on worker productivity: results of a double blind trial. J Allergy Clin Immunol 1990; 85: 296 – 300. 50 de Roeck J, Cluydts R, Herman P. Effects of antihistamines on daytime alertness. J Allergy Clin lmniunol 1990; 85: 179 – 80. 51 Bradley CM, Nicholson AM. Studies on the central effects of the H1 antagonist loratadine. Eur J Clin Pharmacol 1987; 32: 419 – 21. 52 Neves, Pinto RM, Moreira, Lima G., Da Mota Texteira R. A double blind study of the effects of loratadine versus placebo on the performances of pilots. Am J Rhinol 1992; 47: 532 – 4. 53 Ramaekers JG, Uiterwijk MMC, O'Hanlon JF. Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992; 42: 363 – 9. 54 Gengo FM, Dabronzo J, Yurchack A, Lover S, Miller JK. The relative antihistaminic and psychomotor effects of cetirizine and hydroxyzine. Clin Pharmacol Ther 1987; 32: 419 – 21. 55 Gengo FM, Gabos C, Mechtler L. Quantitative effects of cetirizine and diphenhydramine on mental performances measured using an automobile driving simulator. Ann Allergy 1990; 64: 520 – 6. 56 Seidel WF, Cohen S, Bliwise NG, Dement WC. Cetirizine effects on objective measures of daytime sleepiness and performance. Ann Allergy 1987; 59: 58 – 62. 57 Volkerts ER, van Willigenburg APP, van Laar MW, Maes RAA. Does cetirizine belong to the new generalion of antihistamines? An investigation into its acute and subchronic effects on highway driving, psychometric tests. performance and daytime sleepiness. Hum Psychopharmacol 1992; 7: 227 – 38. 58 Levander S, Stahle-Blackdahl M, Hagemark O. Peripheral antihistamines and central sedative effects of single and continuous oral doses of cetirizine and hydroxyzine. Eur J Clin Pharmacol 1991; 41: 435 – 9. 59 Pechadre JC, Beudin P, Eschalier A, Trolese JF, Rihoux JP. A comparison of central and peripheral effects of cetirizine and loratadine. J Int Med Res 1991; 19: 289 – 95. 60 Simons KJ, Dilay DJ, Reggin JD, Fraser TG, Patrick JP, Simons FER. Cetirizine. hydroxyzine, diphenhydramine: studies on central nervous system effects using the P300 event related potential. J Allergy Clin Inimunol 1994; 93: 235. 61 Falliers CJ, Brandon ML, Buchman E, et al. Double blind comparison of cetirizine and placebo in the treatment of seasonal allergic rhinitis. Ann Allergy 1991; 66: 257 – 62. 62 Arriaga F, Rombaut N. Absence of central effects with levocabastine eye drops. Allergy 1990; 45: 552 – 4. 63 Rombaut N, Bhatti JZ, Curran S, Hindmarch I. Effects of topical administration of levocabastine on psychomotor and cognitive functions. Ann Allergy 1991; 67: 75 – 9. 64 McTavish DB, Sorkin EM. Azelastine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1989; 38: 778 – 800. 65 Cohen AF, Hamilton F, Philipson R, Peck AW. The acute effect of acrivastine. a new antihistamine, compared with triprolidine on measures of central nervous system performance and subjective effects. Clin Pharmacol Ther 1985; 38: 381 – 6. 66 Vincent J, Summer DJ, Rcid JL. Ebastine: the effect of a new antihistamine on psychomotor performance and autonomic responses in healthy subjects. Br J Clin Pharmacol 1988; 56: 503 – 8. 67 Brookhuis KA, de Vries G, de Waard D. Acutc and subchronic effects of the H1 histamine receptor antagonist ebastine in 10, 20 and 30 mg dose, and triprolidine 10 mg on car driving performance. Br J Clin Pharmacol 1993; 36: 67 – 70. 68 Wolff AA, Levi R. Histamine and cardiac arrhythmia. Circ Res 1986; 58: 1 – 16. 69 Lauria JI, Markello R, King BD. Circulatory and respiratory effects of hydroxyzine in volunteers and geriatric patients. Curr Res 1958; 47: 378 – 82. 70 Hutcheon DF, Soriahne A, Morris DL. Cardiovascular action of hydroxyzine. J Pharmacol Exp Ther 1959; 18: 451 – 5. 71 Hollister LE. Hydroxyzine hydrochloride: possible adverse cardiac interactions. Psychopharmacol Commun 1971; 1: 61 – 5. 72 Bobik A, McLean AJ. Cardiovascular complications due to pheniramine overdosage. Aust N Z J Med 1976; 6: 65 – 7. 73 Magera BF, Betlach CJ, Sweath AP, Warren Derrick C. Hydroxyzine intoxication in a 13-month-old child. Pediatrics 1981; 87: 280 – 2. 74 Bouju P, Amiot JF, Palacci JH, et al. Intoxication mortelle par la cyproheptadine. Cah Anesthesiol 1985; 33: 265 – 9. 75 Freedberg RS, Friedman GR, Palu RN, Feit F. Cardiogenic shock due to antihistamine overdose. JAMA 1987; 257: 660 – 1. 76 Craft TM. Torsade de pointes after astemizole overdose. BMJ 1986; 292: 660. 77 Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D. Torsade de pointes ventricular tachycardia associated with astemizole overdose. Br J Clin Pract 1988; 42: 257. 78 Simons FER, Kesselmann MS, Giddings NG, Pelech AN, Simons KJ. Asternizole-induced torsade de pointes. Lancet 1988; 45: 624. 79 Bishop RO, Gaudry PL. Prolonged Q-T interval following astemizole overdose. Arch Emerg Med 1989; 6: 63 – 5. 80 Davies AJ, Harindra V, McEwan A, Ghose RR. Cardiotoxic effect with convulsion in terfenadine overdose. BMJ 1989; 298: 325. 81 McConnel TJ, Stanner AJ. Torsade de pointes complicating treatment with terfenadine. BMJ 1991; 302: 1469. 82 Monahan BP, Ferguson CL, Killeavy ES, et al. Torsade de pointes occurring in association with terfenadine use. JAMA 1990; 264: 2788 – 90. 83 Tobin JR, Doyle PT, Ackermann AD, Brenner JI. Astemizole-induced cardiac conduction disturbances in a child. JAMA 1991; 266: 2737 – 40. 84 Hoppu K, Tikanoja T, Tapanainen P, Remes M, Saarenpaa-Heikkila O, Kouvlainen K. Accidental astemizole overdosc in young children. Lancet 1991; 338: 538. 85 Clark A, Love H. Astemizole-induced ventricular arrhythmia: an unexpected cause of convulsions. Int J Cardiol 1991; 33: 165 – 7. 86 Broadhurst P, Nathan AV. Cardiac arrest in a young woman with the long Q-T syndrome and concomitant astemizole ingestion. Br Heart J 1993; 70: 469 – 70. 87 Sakemi H, van Natta B. Torsade de pointes induced by astemizole in a patient with prolongation of the Q-T interval. Am Heart J 1993; 125: 1436 – 8. 88 Venturini E, Borghi E, Maurini V, Vecce R, Carnicelli A. Prolongation of the Q-T interval and hyperkinetic ventricular arrhythmia probably induced by terfenadine use in liver cirrhosis patients. Recenti Prog Med 1992; 83: 21 – 2. 89 Saviuc P, Danel A, Dixmerias T. Prolonged Q-T interval and torsade de pointes following astemizole overdose. Clin Toxicol 1993; 31: 121 – 5. 90 Wiley JF II, Gelber ML, Henretig FM, Wiley CC, Sandhu F. Cardiotoxic effects of astemizole overdose in children. J Pediatr 1992; 120: 799 – 802. 91 Good AP, Rockwood R, Schad P. Loratadine and ventricular tachycardia. Am J Cardiol 1994; 74: 207. 92 Strattmann HG, Kennedy HL. Torsade de pointes associated with drugs and toxins: recognition and management. Am Heart J 1987; 88: 1470 – 82. 93 Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR. Changes in the pharmacokinetics and electrocardio-graphic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231 – 8. 94 Eller MG, Okerholm RA. Pharmacokinetic interaction between terfenadine and ketoconazole. Clin Pharmacol Ther 1991; 49: 130. 95 Pohjola-Sintonen S, Viitasalo M, Toivonene L, Neuvonen P. Torsade de pointes after terfenadine-itraconazole interaction. BMJ 1993; 306: 186. 96 Crane JK, Smith HT. Syncope and cardiac arrhythmia due to interaction between itraconazole and terfenadine. Am J Med 1993; 95: 445 – 6. 97 Zimmermann M, Duruz H, Guinand O, et al. Torsade de pointes after treatment with terfenadine and ketoconazole. Eur Heart J 1992; 13: 1002 – 3. 98 Moore N, Noblet C, Paux G. Torsade de pointes aux antihistaminiques H1. Therapie 1992; 47: 383 – 4. 99 van Peer A, Crabbe R, Woestenborghs R, Heykants J, Janssens M. Ketoconazole inhibits loratadine metabolism in man. Allergy 1993; 48 Suppl 16: 34. 100 Pessayre D. Effects of macrolide antibiotics on drug metabolism in rats and humans. Int J Clin Pharmacol Res 1983; 6: 449 – 58. 101 Hey JA, Del, Prado M., Sherwood J, Kreutner W, Egan WR. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects. Arzneimittelforschung 1996; 46(1): 3 – 8. 102 Hey JA, Del, Prado M., Kreutner W, Egan WR. Cardiotoxic and drug interaction profile of the second generation antihistamines ebastine and terfenadine in experimental animal model of torsade de pointes. Arzneimittelforschung 1996; 46(1): 3 – 7. 103 Warin RP. Torsade de pointes complicating treatment with terfenadine. BMJ 1991; 303: 411. 104 Offenloch K, Kahner G. Rated performance, cardiovascular and quantitative EEG parameters during simulated instrument flight under the effect of terfenadine. Arzneimittelforschung 1992; 42: 864 – 8. 105 Affrime MB, Lorber R, Danzig M, Cuss F, Brannan MD. Three months' evaluation of electrocardiographic effects of loratadine in humans. Allergy 1993; 48 Suppl 16: 29. 106 Woolsey RL, Barby JT, Chung M. Lack of electrocardiographic effects of cetirizine in healthy humans. J Allergy Clin Immunol 1993; 91: 258. 107 Sanders RL, Dockhorn RJ, Alderman JL, McSorley PA, Wenger TL, Frosolono MF. Cardiac effect of acrivastine compared to terfenadine. J Allergy Clin Immunol 1992; 89: 183. 108 Hanrahan R, Choo PW, Carlson W, Greineder D, Faich GA. Antihistamines associate sudden death, ventricular arrhythmia, syncope and Q-T interval prolongation: a comparison of terfenadine and other antihistamines. Post-Marketing Surveillance 1992; 6: 23 – 4. 109 Brandes LJ, Arron RJ, Bogdanovic PR, et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 1992; 52: 3796 – 800. 110 Brandes LJ, Warrington C, Arron RJ, et al. Enhanced cancer growth in mice administered daily human-equivalent doses of some H1 antihistamines: predictive in vitro correlates. J Natl Cancer Inst 1994; 86: 770 – 5. 111 Weed DL. Between science and technology: the case of antihistamines and cancer. J Natl Cancer Inst 1994; 86: 755 – 6. 112 Mathews J. Concern over Prozac-induced tumor growth may dwindle following FDA study. J Natl Cancer Inst 1995; 87: 1285 – 7. 113 FDA reviews antihistamine mouse study. FDA Talk Paper, 17 May 1994. 114 Simons FER, Simons KJ. The pharmacology and use of H, receptor antagonist drugs. N Engl J Med 1994; 330: 1663 – 70. 115 Campoli-Richards DM, Buckley MMT, Fitton A. Cetirizine. A review of its pharmacological properties and clinical potential in allergic rhinitis, pollen induced asthma and chronic urticaria. Drugs 1990; 40: 761 – 81. 116 Dechant KL, Goa KL. Levocabastine. A review of its pharmacological properties and therapeutic potential as a topical antihistamine in allergic rhinitis and conjunctivitis. Drugs 1991; 41: 202 – 24. 117 Hindmarch I. Psychometric aspects of antihistamines. Allergy 1995; 50 Suppl 24: 48 – 54. 118 O'Hanlon JF, Ramaekers JG. Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience, 1989–94. Allergy 1995; 50: 234 – 42. 119 Nightingale SL. Warning issued on nonsedating antihistamines terfenadine and astemizole. JAMA 1992; 268: 6. Citing Literature Volume51, Issue10October 1996Pages 666-675 ReferencesRelatedInformation" @default.
• W2023346881 created "2016-06-24" @default.
• W2023346881 creator A5004618013 @default.
• W2023346881 creator A5005433688 @default.
• W2023346881 creator A5005978055 @default.
• W2023346881 creator A5006142596 @default.
• W2023346881 creator A5009457305 @default.
• W2023346881 creator A5019154798 @default.
• W2023346881 creator A5028418429 @default.
• W2023346881 creator A5043192106 @default.
• W2023346881 creator A5046878619 @default.
• W2023346881 creator A5055677585 @default.
• W2023346881 creator A5068824951 @default.
• W2023346881 creator A5070496395 @default.
• W2023346881 creator A5073839386 @default.
• W2023346881 creator A5075387555 @default.
• W2023346881 date "1996-10-01" @default.
• W2023346881 modified "2023-10-14" @default.
• W2023346881 title "The clinical safety of H₁receptor antagonists An EAACI position paper" @default.
• W2023346881 cites W1501218918 @default.
• W2023346881 cites W1510817051 @default.
• W2023346881 cites W1886529396 @default.
• W2023346881 cites W1898430231 @default.
• W2023346881 cites W1940485884 @default.
• W2023346881 cites W1966037864 @default.
• W2023346881 cites W1968796734 @default.
• W2023346881 cites W1969912683 @default.
• W2023346881 cites W1971271453 @default.
• W2023346881 cites W1974678893 @default.
• W2023346881 cites W1977382668 @default.
• W2023346881 cites W1978702424 @default.
• W2023346881 cites W1986087589 @default.
• W2023346881 cites W1991100098 @default.
• W2023346881 cites W1994861329 @default.
• W2023346881 cites W2007842184 @default.
• W2023346881 cites W2011871801 @default.
• W2023346881 cites W2012908981 @default.
• W2023346881 cites W2016523948 @default.
• W2023346881 cites W2023671946 @default.
• W2023346881 cites W2031745592 @default.
• W2023346881 cites W2033863659 @default.
• W2023346881 cites W2035530472 @default.
• W2023346881 cites W2036751553 @default.
• W2023346881 cites W2039031830 @default.
• W2023346881 cites W2045713465 @default.
• W2023346881 cites W2047963115 @default.
• W2023346881 cites W2052546951 @default.
• W2023346881 cites W2053317199 @default.
• W2023346881 cites W2057124895 @default.
• W2023346881 cites W2063178406 @default.
• W2023346881 cites W2065349363 @default.
• W2023346881 cites W2069296060 @default.
• W2023346881 cites W2071202348 @default.
• W2023346881 cites W2072293643 @default.
• W2023346881 cites W2074434978 @default.
• W2023346881 cites W2074949244 @default.
• W2023346881 cites W2074990289 @default.
• W2023346881 cites W2078775644 @default.
• W2023346881 cites W2081630005 @default.
• W2023346881 cites W2089924434 @default.
• W2023346881 cites W2096565938 @default.
• W2023346881 cites W2107077717 @default.
• W2023346881 cites W2120917180 @default.
• W2023346881 cites W2131366651 @default.
• W2023346881 cites W2136506094 @default.
• W2023346881 cites W2141715023 @default.
• W2023346881 cites W2143183230 @default.
• W2023346881 cites W2144536820 @default.
• W2023346881 cites W2160849818 @default.
• W2023346881 cites W2161927647 @default.
• W2023346881 cites W2170108483 @default.
• W2023346881 cites W2287611346 @default.
• W2023346881 cites W2313064083 @default.
• W2023346881 cites W2407230944 @default.
• W2023346881 cites W4233331038 @default.
• W2023346881 cites W4241595836 @default.
• W2023346881 cites W4255285279 @default.
• W2023346881 cites W2020301509 @default.
• W2023346881 doi "https://doi.org/10.1111/j.1398-9995.1996.tb02109.x" @default.
• W2023346881 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8904993" @default.
• W2023346881 hasPublicationYear "1996" @default.
• W2023346881 type Work @default.
• W2023346881 sameAs 2023346881 @default.
• W2023346881 citedByCount "25" @default.
• W2023346881 countsByYear W20233468812012 @default.
• W2023346881 countsByYear W20233468812013 @default.
• W2023346881 countsByYear W20233468812016 @default.
• W2023346881 countsByYear W20233468812017 @default.
• W2023346881 countsByYear W20233468812022 @default.
• W2023346881 crossrefType "journal-article" @default.
• W2023346881 hasAuthorship W2023346881A5004618013 @default.
• W2023346881 hasAuthorship W2023346881A5005433688 @default.
• W2023346881 hasAuthorship W2023346881A5005978055 @default.
• W2023346881 hasAuthorship W2023346881A5006142596 @default.
• W2023346881 hasAuthorship W2023346881A5009457305 @default.
• W2023346881 hasAuthorship W2023346881A5019154798 @default.
• W2023346881 hasAuthorship W2023346881A5028418429 @default.
• W2023346881 hasAuthorship W2023346881A5043192106 @default.

• next